Does aspirin add any advantage to intravenous immunoglobulin (IVIG) alone in children with Kawasaki disease (KD)? A randomized clinical trial IVIG alone was not inferior to IVIG plus aspirin, suggesting that high-dose aspirin during initial IVIG treatment did not reduce coronary artery lesions (CAL).
Dr. John Cush RheumNow
1 year 3 months ago
Should Lupus Nephritis Receive PJP Prophylaxis?
A current review article suggests that the need for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in patients with systemic lupus erythematosus (SLE) and lupus nephritis will need to be individualized based on therapies and https://t.co/zzRIVG0Sq3
BSR RheumatologyUK
1 year 3 months ago
#JIA #biologics and #tsDMARDs: Are all patients getting the same access? MDTs, share your insights on on-label and off-label prescribing and help improve future care.
đź’¬ Take the survey by 15 April: https://t.co/vC2Pv5vmH4 https://t.co/rRM5rH0QQl
Nelly ZIADE 🍀 Nellziade
1 year 3 months ago
🚨 New publication alert!
We review the latest advances in imaging for axial spondyloarthritis—from high-res MRI and synthetic CT to deep learning algorithms improving lesion detection.
đź”— https://t.co/oddjoFOGzM
#AxSpA #AIinMedicine
@XBaraliakos @WalterMaks @krystelaouad https://t.co/VwuUwYL1Xs
Dr. John Cush RheumNow
1 year 3 months ago
FDA reports higher rate of allergic/hypersensitivity type reactions w/ certainlots of Immune Globulin Intravenous (IGIV) and Immune Globulin Subcutaneous (IGSC) ; these have voluntarily withdrawn by the manufacturers https://t.co/N73Cc8rfAS https://t.co/OTROyomvv8
Dr. John Cush RheumNow
1 year 3 months ago
Full read state of the art review of treatments for Axial Spondyloarthritis
Concluding unmet needs:
-Suboptimal Tx Response
- Limited Drug Options
- No Biomarkers
- Extra-Axial Dz
- Non-Inflammatory Pain https://t.co/K3oqRCgTCP https://t.co/IPn09jMFM2
Dr. John Cush RheumNow
1 year 3 months ago
Pregnancy-Related Deaths in the US
A CDC cross-sectional national study showed an increase in pregnancy-related deaths in the US from 2018 to 2022, with highest rates among American Indian, Alaska Native women, and non-Hispanic Black women.
https://t.co/H1s649GyiL https://t.co/MXnrQrAcrT
Dr. John Cush RheumNow
1 year 4 months ago
ACP: Best Practice Advice on Cannabis or Cannabinoids Use for Chronic Noncancer Pain
The American College of Physicians published a best practice advisory on cannabis or cannabinoids in the Annals of Internal Medicine.
https://t.co/B0eWstjN0Z https://t.co/IzSEIeosme
Dr. John Cush RheumNow
1 year 4 months ago
"Don’t ever let anyone tell you you ain’t strong enough" – Janis Joplin https://t.co/1B1YD5gDLk
Dr. John Cush RheumNow
1 year 4 months ago
Uveitis Risk with Slow Adalimumab Weaning
Patients with pediatric non-infectious uveitis (NIU) who achieved remission on adalimumab (Humira) had lower recurrence rates when the drug was withdrawn more gradually, a retrospective cohort analysis indicated. https://t.co/KgQsK6fVnr
Dr. John Cush RheumNow
1 year 4 months ago
2nd Opinions in Rheumatology
https://t.co/R4CjJHEaL4 https://t.co/0quDwdANyU
Dr. John Cush RheumNow
1 year 4 months ago
Vamorolone: a New Steroid on the Horizon?
Vamorolone is a potentially new alternative to traditional glucocorticoids for use in inflammatory diseases. It is a dissociated steroidal compound with reduced side effects, and in an animal model of inflammation has shown effective https://t.co/38WTOAuuJy
Antoni Chan MD (Prof) synovialjoints
1 year 4 months ago
Summary of the updated BSR Axial Spondyloarthritis for biological and targeted synthetic DMARD guidelines 2025 @RheumatologyUK #axialspondyloarthritis
Full paper available at:
https://t.co/LytDiHjawi https://t.co/iaHzD1BQRe
BSR RheumatologyUK
1 year 4 months ago
📢Calling all paediatrics! #BSR25 is almost here - Check out our top paediatric highlights from a packed Annual Conference programme 🔗Read our latest blog now: https://t.co/8uJMiqg2fW https://t.co/PAASNk3ZuF
BSR RheumatologyUK
1 year 4 months ago
Prof Ian Giles will be covering a range of topics at this year's Rheumapreg Conference such as how immunologic changes and placental dysfunction cause adverse outcomes in rheumatic disease pregnancies.
View the full prgramme and learn more: https://t.co/tjiycjKJ8i https://t.co/FugHvtm8fY
